Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Press release from the Extra General Meeting August 13, 2018

Mon, Aug 13, 2018 19:00 CET

The Extra General Meeting (EGM) of Vicore Pharma Holding AB (publ) was held today August 13, 2018. The EGM passed resolutions regarding, among other thing, the following.Dividends of shares in I-Tech AB (publ) It was resolved that a dividend in kind of one share in I-Tech AB (publ) (“I-Tech”) is to be distributed for eight shares in Vicore Pharma Holding AB (publ). That is equivalent to a total of 1,983,563 shares in I-Tech. Based on the shares’ booked value in the Company’s quarterly report on 31 March 2018, the proposed dividend corresponds to approximately SEK 0.77 per share and in

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Press release from the Extra General Meeting August 13, 2018

Media